Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 78 entries
View as:

Treatment of Adults With Growth Hormone Deficiency

Phase: N/A Priority: Normal
NCT ID: NCT00596037 Org: User:
Start: 08/31/06 End: 05/31/09 Due: 05/31/10

Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.

Phase: N/A Priority: Normal
NCT ID: NCT03015909 Org: User:
Start: 08/11/16 End: 12/21/17 Due: 12/21/18

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.

Phase: N/A Priority: Normal
NCT ID: NCT02056600 Org: User:
Start: 03/31/14 End: 05/31/14 Due: 05/31/15

Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

Phase: N/A Priority: Normal
NCT ID: NCT01990469 Org: User:
Start: 01/31/14 End: 04/30/15 Due: 04/30/16

Clinical Study to Evaluate the Correction of Facial Wrinkles and Folds and Safety of YVOIRE Volume Versus Perlane in Nasolabial Fold Injection

Phase: N/A Priority: Normal
NCT ID: NCT03738007 Org: User:
Start: 03/31/10 End: 12/31/10 Due: 12/31/11

BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone

Phase: N/A Priority: Normal
NCT ID: NCT01662674 Org: User:
Start: 10/31/12 End: 03/31/13 Due: 03/31/14

Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO

Phase: N/A Priority: Normal
NCT ID: NCT01624571 Org: User:
Start: 03/31/12 End: 10/31/12 Due: 10/31/13

Bioequivalence of LB80380 Free Base and Maleate Salt Tablets

Phase: N/A Priority: Normal
NCT ID: NCT01427868 Org: User:
Start: 09/30/10 End: 12/31/10 Due: 12/31/11

Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s

Phase: N/A Priority: Normal
NCT ID: NCT02334358 Org: User:
Start: 09/30/14 End: 08/31/16 Due: 08/31/17

Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02426151 Org: User:
Start: 04/30/15 End: 09/30/15 Due: 09/30/16

Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01918709 Org: User:
Start: 09/30/11 End: 11/30/11 Due: 11/30/12

Efficacy and Safety of LBSA0103 Versus Hyruan Plus Injection in Patients With Knee Osteoarthritis

Phase: N/A Priority: Normal
NCT ID: NCT01510535 Org: User:
Start: 12/31/11 End: 10/31/12 Due: 10/31/13

A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)

Phase: N/A Priority: Normal
NCT ID: NCT01968044 Org: User:
Start: 10/31/13 End: 10/31/15 Due: 10/31/16

A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02357069 Org: User:
Start: 02/28/15 End: - Due: -

Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study

Phase: N/A Priority: Normal
NCT ID: NCT02119793 Org: User:
Start: 05/31/15 End: 08/31/16 Due: 08/31/17

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

Phase: N/A Priority: Normal
NCT ID: NCT01918332 Org: User:
Start: 04/30/12 End: 03/31/13 Due: 03/31/14

Safety and Efficacy Study of LB80380 in the Patients With Lamivudine-Refractory Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT00895596 Org: User:
Start: 03/31/04 End: 12/31/07 Due: 12/31/08

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

Phase: N/A Priority: Normal
NCT ID: NCT01578304 Org: User:
Start: 12/31/10 End: 10/31/11 Due: 10/31/12

Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02004587 Org: User:
Start: 09/30/13 End: 07/31/14 Due: 07/31/15

Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)

Phase: N/A Priority: Normal
NCT ID: NCT01747083 Org: User:
Start: 01/31/13 End: 04/30/13 Due: 04/30/14

Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02089126 Org: User:
Start: 06/30/14 End: - Due: -

Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of LC15-0444 and Metformin After Oral Administration in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01426399 Org: User:
Start: 08/31/11 End: 12/31/11 Due: 12/31/12

Pharmacokinetics and Safety Study of Apetrol ES

Phase: N/A Priority: Normal
NCT ID: NCT02446353 Org: User:
Start: 04/30/10 End: 10/31/10 Due: 10/31/11

BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone

Phase: N/A Priority: Normal
NCT ID: NCT02670070 Org: User:
Start: 03/31/16 End: 06/30/16 Due: 06/30/17

Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT01026610 Org: User:
Start: 08/31/09 End: 05/31/11 Due: 05/31/12